Exelixis ((EXEL)), Novartis AG ((NVS)), Bristol-Myers Squibb Company ((BMY)), Clovis Oncology Inc ((CLVSQ)), DEL_Novartis (0QM7) ((DEL_0QM7)), DEL_Novartis Inc ((DEL_0QLR)), Novartis ((CH:NOVN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The Pan Tumor Rollover Study, officially titled ‘Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies,’ aims to evaluate the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This study is significant as it seeks to provide insights into the prolonged effects and safety of these treatments, potentially influencing future cancer therapies.
The study tests several interventions, primarily focusing on the drug nivolumab, either alone or in combination with other drugs like ipilimumab, cabozantinib, and relatlimab. These interventions are designed to treat different cancer types, aiming to improve patient outcomes by exploring various drug combinations.
The study is interventional, non-randomized, and follows a parallel assignment model with no masking, primarily aimed at treatment. This design allows for a straightforward evaluation of the safety and efficacy of the interventions in a real-world setting.
The study began on August 9, 2019, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on July 24, 2025, indicating ongoing progress and adjustments as the study evolves.
This update could impact the stock performance of involved companies like Bristol-Myers Squibb, Exelixis, and Novartis, as positive results may boost investor confidence and market value. The study’s outcomes could also influence the competitive landscape in the oncology sector, affecting companies like Clovis Oncology and others in the industry.
The Pan Tumor Rollover Study is currently recruiting, with further details available on the ClinicalTrials portal.